1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)

Authors :: Tuomo Alanko
Akseli Hemminki
Víctor Cervera-Carrascón
João Santos
Riikka Havunen
Juha Kononen
Jorma Sormunen
Katriina Peltola
Riitta Korpisaari
Susanna Juteau
Marjut Jaakkola
Suvi Sorsa
Santeri A Pakola
James Clubb
Elise Jirovec
Dafne CA Quixabeira
Lyna Haybout
Claudia Kistler
Tatiana V Kudling
Source :: Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Publication Year :: 2023
Publisher :: BMJ Publishing Group, 2023.

Subjects :: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Full Text Access

Tools